Transcept Pharmaceuticals to Present at 11th Annual BIO CEO & Investor Conference
February 05 2009 - 9:00AM
PR Newswire (US)
PT. RICHMOND, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Transcept
Pharmaceuticals, Inc. announced today that Glenn A. Oclassen,
President & Chief Executive Officer, is scheduled to present at
the 11th Annual BIO CEO & Investor Conference in New York City
on Monday, February 9, 2009 at 9:30 AM Eastern Time. An audio
webcast of the presentation will be available at
http://www.transcept.com/. The replay of the presentation will be
available for 30 days. About Transcept Pharmaceuticals (TSPT)
Transcept Pharmaceuticals is a specialty pharmaceutical company
focused on the development and commercialization of proprietary
products that address important therapeutic needs in the fields of
psychiatry and sleep medicine. On February 2, 2009, Transcept
completed a merger with Novacea, Inc. As part of the transaction,
Novacea changed its name to "Transcept Pharmaceuticals, Inc." and
its NASDAQ ticker symbol to "TSPT." The combined company resources
resulting from the merger are expected to enable Transcept to
successfully commercialize its lead product candidate,
Intermezzo(R). If approved, Intermezzo(R) is positioned to be the
first commercially available sleep aid specifically for use in the
middle of the night when patients awaken and have difficulty
returning to sleep. Intermezzo(R) Phase 3 clinical trials have been
completed and, on September 30, 2008, Transcept submitted a New
Drug Application (NDA) for Intermezzo(R) to the U.S. Food and Drug
Administration (FDA) which was accepted for filing on December 15,
2008. The FDA has assigned a PDUFA date of July 30, 2009 to the
Intermezzo(R) NDA. For further information, please visit the
company's website at: http://www.transcept.com/. Safe Harbor This
press release contains forward-looking statements for purposes of
the Private Securities Litigation Reform Act of 1995 (the "Act").
Transcept disclaims any intent or obligation to update these
forward-looking statements, and claims the protection of the Safe
Harbor for forward-looking statements contained in the Act.
Examples of such statements include, but are not limited to,
statements relating to Intermezzo being the first commercially
available sleep aid in its target indication. Such statements are
based on management's current expectations, but actual results may
differ materially due to various risks and uncertainties,
including, but not limited to positive results in clinical trials
may not be sufficient to obtain FDA approval; physician or patient
reluctance to use Intermezzo(R), if approved; potential alternative
therapies; maintaining adequate patent or trade secret protection
without violating the intellectual property rights of others; and
other difficulties or delays in, or unexpected expenses incurred in
connection with, obtaining regulatory approval , market acceptance
and commercialization of Intermezzo(R). Contacts: Transcept
Pharmaceuticals, Inc. Michael Gill Director of Communications (510)
215-3575 The Ruth Group Investors / Media Stephanie Carrington /
Jason Rando (646) 536-7017 / 7025 DATASOURCE: Transcept
Pharmaceuticals, Inc. CONTACT: Michael Gill, Director of
Communications of Transcept Pharmaceuticals, Inc., +1-510-215-3575,
; or Investors, Stephanie Carrington, +1-646-536-7017, , or Media,
Jason Rando, +1-646-536-7025, , both of The Ruth Group for
Transcept Pharmaceuticals, Inc. Web site: http://www.transcept.com/
Copyright